Abstract:
Cardiotonically active 19-alkylene-14 Beta -hydroxycardenolides of the formula
WHEREIN R1 taken alone is -CH, -CO2R5, -CON(R6)2, -CH(OR6)2, C6H5, -CH CH2, or -SCH3, or, taken together with an -OH group in the R3-position, forms a lactone ring; R2 is -H, -CH3, -F, -Cl, Br, or -I; R3 is 5 Alpha -H, 5 Beta -H, or 5 Beta -OH; R4 is -OH, substituted or unsubstituted 3-pyranyl ether, or a 5-or 6membered substituted or unsubstituted cyclic glycoside; R5 is -H, -CH3, -C2H5, -C3H7, -C4H9, -C5H11, or -CH2-C6H5; and R6 is -CH3 or -C2H5, or, when -CH(OR6)2 is a cyclic acetal, the R6''s together are -CH2CH2- or -CH2C(CH3)2CH2-. A process for preparing these compounds from the corresponding 19-oxo-14 Beta hydroxy cardenolides.
Abstract:
A 14B-HYDROXY-3-OXO-5A-CARD-20(22)-ENOLIDE IS PREPARED BY KETALIZING A 3-OXO-5A-CARDA-14,20(22)-DIENOLIDE, COVERING THE 3-KETAL SO OBTAINED WITH AN N-HALOGENOAMIDE UNDER WHEAKLY ACID CONDITIONS INTO A 3-KETAL OF A 3-OXO-14B-HYDROXY-15A-BROMO-5A-CARD-20(22)ENOLIDE, CATALYTICALLY HYDROGENATING THIS KETAL TO FORM THE CORRESPONDING 3-OXO-14B-HYDROXY-5A-CARD-20 (22)-ENOLIDE, THE PH VALUE BEING BETWEEN 4.5 AND 7, AND SPLITING OFF THE 3-KETAL GROUP UNDER WEAKLY ACID CONDI TIONS. THE PRODUCTS OF INVENTION HAVE VALUABLE PHARMACOLOGICAL PROPERTIES.
Abstract:
(ANDROST-17-B-YL)-A-PYRONES, CARDIOACTIVE PER SE AND USEFUL AS INTERMEDIATES IN THE MANUFACTURE OF SCILLARENONE AND SCILLARENIN, AND METHODS FOR MAKING THE SAME BY RING CLOSURE OF 20-ALKOXYMETHYLENE-21-CARBALKOXYMETHYLENE OR 20-FORMYL-21-CARBALKOXYMETHYLENE STEROIDS DERIVED FROM 21-DIALKOXY-20-KETO STEROID STARTING COMPOUNDS.
Abstract:
Cardenolide-3-(2''-desoxy-glycosides) of the formula
useful in the treatment of cardiac and circulatory diseases, wherein R1 is a steroid of the 3-hydroxy-cardenolide series, R2 is hydrogen, lower aliphatic acyl, or aromatic acyl, and R3 is hydrogen, methyl, or -CH2OR2.
Abstract:
Delta 14-20-KETO-21-DIALKOXY STEROIDS ARE PREPARED BY OXIDIZING 20-KETO-15 Alpha ,21-DIHYDROXY STEROIDS OF THE GENERAL FORMULA
IN WHICH Y is an oxo group which may be ketalized, a
GROUP WHICH MAY BE ETHERIFIED OR ESTERIFIED, A Delta 3-, Delta 2-, OR Delta 3,5-ENOL ETHER GROUP OR A Delta 3-, Delta 2-, OR Delta 3,5-ENAMINO GROUP, WHICH GROUPS MAY HAVE A DOUBLE BOND IN THE 4-POSITION, AND
IS A LOWER ACYCLIC OR CYCLIC ACETAL GROUPING, ACETALIZING THE 15 Alpha -HYDROXY-20-KETO-21-OXO STEROIDS OBTAINED, REACTING THE 15 Alpha -HYDROXY-20-KETO-21-DIALKOXY STEROIDS THUS OBTAINED WITH SULFONIC ACID HALIDES AND TREATING THE 15-SULFONIC ACID ESTERS THUS OBTAINED WITH AGENTS SPLITTING OFF ACIDS. The products are valuable intermediates for the manufacture of medicaments.
Abstract:
The present invention relates to an improved process for the manufacture of Beta -(3-oxo-7 Alpha -thioacyl-17 Beta -hydroxy4-androstene-17 Alpha -yl)-propionic acid gamma -lactones in which a Beta -(3-oxo-17 Beta -hydroxy-4,6-androstadiene-17 gamma -yl)-propionaldehyde cyclohemiacetal alkyl glycoside is reacted with a thiocarboxylic acid in a mixture of water and an organic solvent miscible with water to yield a 3-(3''-oxo-7 Alpha ''thioacyl-17 Beta ''-hydroxy-4''-androstene-17 Alpha ''-yl)propionaldehyde cyclohemiacetal alkyl glycoside and in which the compound thus obtained is oxidized in an acid solution, the alkyl glycoside radical in the cyclohemiacetal group being split off, to yield the corresponding gamma -lactone; the invention further relates to new intermediates useful in this process and having the formula
IN WHICH R1 stands for the methyl group or a hydrogen atom and R2 and R3 each for an alkyl group having 1 to 5 carbon atoms.